Sort
10,766 grants matching “checkpoint inhibitor”
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ
$554,314Robert C Rostomily · Methodist Hospital Research Institute · R01 · FY2025 · NS
Advancing RAS pathway targeted therapy in NF1-MPNST: effects of SHP2 and CDK4/6 inhibitors on the tumor and the tumor immune microenvironment
$554,153Christine Anne Pratilas · Johns Hopkins University · R01 · FY2023 · CA
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy
$553,817Yaguang Xi · Lsu Health Sciences Center · R01 · FY2022 · CA
Delineating Functional Immunity via Image-Guided PET
$553,790Nerissa Therese Viola · Wayne State University · R37 · FY2024 · CA
Role of IRF2 in cancer immune evasion and immunotherapy
$553,729Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2024 · CA
Overcoming hypoxic resistance to anti-cancer therapy
$553,580Nicholas C Denko · Ohio State University · R01 · FY2024 · CA
CAREER: Engineered multispecific antibodies to interrogate and manipulate immune checkpoint protein trafficking
$553,546Jamie Spangler · Johns Hopkins University · · FY2022 · ENG
Drugging EBNA1 to Treat EBV-Associated Cancers
$553,343Troy E Messick · Wistar Institute · R01 · FY2024 · CA
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma
$553,260Steven W. Dow · Colorado State University · U01 · FY2020 · CA
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
$553,064Andre Elias Nel · University Of California Los Angeles · R01 · FY2021 · CA
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
$553,064Andre Elias Nel · University Of California Los Angeles · R01 · FY2020 · CA
Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment
$552,945Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Biomarkers for acute interstitial nephritis in humans
$552,936Dennis G. Moledina · Yale University · R01 · FY2024 · DK
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial
$552,880Lei Zheng · Johns Hopkins University · R01 · FY2023 · CA
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy
$552,877Xue-Zhong Yu · Medical College Of Wisconsin · R01 · FY2022 · CA
Radiogenomic Credentialing of Head and Neck Cancer Models
$552,668Mukund Seshadri · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome
$552,594Lajos Pusztai · Yale University · R01 · FY2017 · CA
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer
$552,591Jin Xie · University Of Georgia · R01 · FY2021 · CA
Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer
$552,535Deborah W Knapp · Purdue University · U01 · FY2023 · CA
Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors
$552,492Michael Karin · University Of California, San Diego · R01 · FY2021 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy
$552,383Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma
$552,266Chun Li · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Integrated Discovery Pipeline for Tumor Neoantigens
$552,250Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2018 · CA
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma
$552,171Steven W. Dow · Colorado State University · U01 · FY2022 · CA
Re-wiring PDAC Tumor Immunity Through Dendritic Cells
$551,987David G Denardo · Washington University · R01 · FY2021 · CA